Is Xeris Biopharma Holdings Inc (NASDAQ:XERS) A Better Buy Than Others After A 77.78% Rise In This Year?

In last trading session, Xeris Biopharma Holdings Inc (NASDAQ:XERS) saw 0.89 million shares changing hands with its beta currently measuring 1.83. Company’s recent per share price level of $3.28 trading at -$0.17 or -4.93% at ring of the bell on the day assigns it a market valuation of $488.99M. That closing price of XERS’s stock is at a discount of -10.98% from its 52-week high price of $3.64 and is indicating a premium of 48.48% from its 52-week low price of $1.69. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.35 million shares which gives us an average trading volume of 1.61 million if we extend that period to 3-months.

For Xeris Biopharma Holdings Inc (XERS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.33. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.06 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Xeris Biopharma Holdings Inc (NASDAQ:XERS) trade information

Upright in the red during last session for losing -4.93%, in the last five days XERS remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $3.28 price level, adding 6.82% to its value on the day. Xeris Biopharma Holdings Inc’s shares saw a change of 39.57% in year-to-date performance and have moved 7.89% in past 5-day. Xeris Biopharma Holdings Inc (NASDAQ:XERS) showed a performance of 1.55% in past 30-days. Number of shares sold short was 10.15 million shares which calculate 5.67 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 5.75 to the stock, which implies a rise of 42.96% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 6.6. It follows that stock’s current price would jump 8.54% in reaching the projected high whereas dropping to the targeted low would mean a gain of 8.54% for stock’s current value.

Xeris Biopharma Holdings Inc (XERS) estimates and forecasts

Statistics highlight that Xeris Biopharma Holdings Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 45.45% of value to its shares in past 6 months, showing an annual growth rate of 8.89% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 21.83% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 56.74M for the same. And 3 analysts are in estimates of company making revenue of 53.67M in the next quarter. Company posted 44.39M and 40.64M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 38.13% during past 5 years.

Xeris Biopharma Holdings Inc (NASDAQ:XERS)’s Major holders

Insiders are in possession of 3.92% of company’s total shares while institution are holding 43.81 percent of that, with stock having share float percentage of 45.60%. Investors also watch the number of corporate investors in a company very closely, which is 43.81% institutions for Xeris Biopharma Holdings Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at XERS for having 10.33 million shares of worth $23.25 million. And as of 2024-06-30, it was holding 7.3531 of the company’s outstanding shares.

The second largest institutional holder is VANGUARD GROUP INC, which was holding about 7.66 million shares on 2024-06-30. The number of shares represents firm’s hold over 5.4492 of outstanding shares, having a total worth of $17.23 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 4.25 shares of worth $13.96 million or 2.85% of the total outstanding shares. The later fund manager was in possession of 3.74 shares on Aug 31, 2024 , making its stake of worth around $12.26 million in the company or a holder of 2.51% of company’s stock.